Rhumbline Advisers Has $29.19 Million Stock Holdings in Penumbra, Inc. (NYSE:PEN)

Rhumbline Advisers decreased its position in Penumbra, Inc. (NYSE:PEN - Free Report) by 1.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 109,147 shares of the company's stock after selling 1,239 shares during the quarter. Rhumbline Advisers owned about 0.28% of Penumbra worth $29,187,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. GAMMA Investing LLC lifted its stake in Penumbra by 42,409.9% during the first quarter. GAMMA Investing LLC now owns 189,594 shares of the company's stock valued at $50,699,000 after purchasing an additional 189,148 shares during the last quarter. Versant Capital Management Inc increased its stake in Penumbra by 893.5% in the 1st quarter. Versant Capital Management Inc now owns 308 shares of the company's stock worth $82,000 after purchasing an additional 277 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Penumbra by 74.7% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 3,115 shares of the company's stock worth $740,000 after buying an additional 1,332 shares during the period. Employees Retirement System of Texas raised its holdings in shares of Penumbra by 31.9% during the fourth quarter. Employees Retirement System of Texas now owns 5,273 shares of the company's stock valued at $1,252,000 after acquiring an additional 1,274 shares during the period. Finally, Jefferies Financial Group Inc. acquired a new position in Penumbra in the 4th quarter worth approximately $760,000. Institutional investors own 88.88% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on PEN shares. Stifel Nicolaus set a $318.00 price target on shares of Penumbra and gave the stock a "buy" rating in a research report on Thursday, April 24th. Truist Financial raised their price target on Penumbra from $315.00 to $330.00 and gave the stock a "buy" rating in a research note on Thursday, April 24th. Needham & Company LLC reiterated a "hold" rating on shares of Penumbra in a research note on Wednesday, February 19th. JPMorgan Chase & Co. lifted their price objective on shares of Penumbra from $230.00 to $285.00 and gave the company an "overweight" rating in a research note on Wednesday, February 19th. Finally, Royal Bank of Canada boosted their price target on Penumbra from $315.00 to $330.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Three equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $302.40.

Insider Buying and Selling

In other Penumbra news, CEO Adam Elsesser sold 16,600 shares of the company's stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $276.21, for a total transaction of $4,585,086.00. Following the sale, the chief executive officer now directly owns 27,752 shares of the company's stock, valued at approximately $7,665,379.92. This represents a 37.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Thomas Wilder sold 360 shares of Penumbra stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $264.58, for a total transaction of $95,248.80. Following the completion of the transaction, the director now owns 4,533 shares of the company's stock, valued at $1,199,341.14. This trade represents a 7.36% decrease in their position. The disclosure for this sale can be found here. Insiders sold 128,845 shares of company stock worth $36,359,981 in the last quarter. 4.20% of the stock is owned by corporate insiders.

Penumbra Stock Performance

Shares of NYSE PEN traded up $0.45 during trading hours on Friday, reaching $258.83. The stock had a trading volume of 376,022 shares, compared to its average volume of 449,501. The company has a market cap of $10.02 billion, a price-to-earnings ratio of 761.26, a PEG ratio of 2.83 and a beta of 0.49. Penumbra, Inc. has a twelve month low of $148.00 and a twelve month high of $310.00. The business's fifty day moving average is $277.14 and its two-hundred day moving average is $266.58. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25.

Penumbra (NYSE:PEN - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The company reported $0.83 earnings per share for the quarter, beating analysts' consensus estimates of $0.66 by $0.17. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The firm had revenue of $324.14 million for the quarter, compared to analysts' expectations of $315.72 million. During the same period in the prior year, the business posted $0.41 earnings per share. The business's revenue was up 16.3% compared to the same quarter last year. As a group, research analysts expect that Penumbra, Inc. will post 3.67 EPS for the current year.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.